Gene set for detection of blocking type dyszoospermia, and preparation method and application of gene detection panel thereof

By designing a genetic detection panel for 'blocking' spermatogenesis disorders, the problem of single detection content and unclear classification in the prior art is solved, and efficient and accurate spermatogenesis disorder detection is achieved. It is suitable for self-developed sequencing instruments , reduces costs and expands the scope of application.

CN118942546APending Publication Date: 2024-11-12SHANGHAI FIRST PEOPLES HOSPITAL
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410973245.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the detection of spermatogenesis disorders, the existing technology has problems such as single detection content, fewer gene loci, unclear classification, simple gene collection methods and cumbersome information analysis methods, which are difficult to meet the needs of clinical diagnosis and treatment.

Method used

A panel for gene detection of 'blocking' spermatogenesis disorder was designed. By screening relevant genes, establishing a local database, selecting gene target regions, designing probes, synthesizing RNA probes, and forming a gene detection panel with high coverage. Suitable for high-throughput sequencing platforms.

Benefits of technology

It improves the performance and accuracy of detection, is suitable for self-developed sequencing instruments, reduces detection and analysis costs, expands the scope of application, and has high portability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The invention discloses a gene set for detection of blocking type dyszoospermia, and a preparation method and application of a gene detection panel thereof, and the preparation method comprises the following steps: screening information of blocking type dyszoospermia and related genes thereof, and establishing a local database; the method comprises the following steps: selecting a'retarding type 'spermatogenesis disorder related gene from disclosed literature resources; the method comprises the following steps of: merging related genes of blocking type dyszoospermia, and removing redundancy to obtain a blocking type dyszoospermia detection chip gene set; selecting a gene target area for probe design; extending two ends of the selected gene target area; a panel probe is designed; evaluating probe design; and carrying out panel synthesis. By using the gene detection panel designed by the invention, genetic detection and accurate typing can be efficiently carried out on dyszoospermia only by using a small amount of peripheral blood, and the result has important guiding significance for clinical diagnosis and treatment of such patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of gene detection, and in particular to a gene set for detecting "blocked type" spermatogenesis disorders, a preparation method of a gene detection panel thereof, and applications thereof. Background Art

[0002] In 1985, HULL et al. from the University of Bristol in the United Kingdom proposed that spermatogenesis disorder is a serious clinical disease of fertility disorder. In 1993, the WHO Manual of Standardized Examination and Diagnosis and Treatment of Male Infertility pointed out that spermatogenesis disorder has significant heterogeneity. For diagnostic classification, testicular histological types can be divided into: 1) Spermatozoa can be seen in the seminiferous tubules (or parts): spermatogenic cells of all levels can be seen in most (or part) of the seminiferous tubules; 2) No sperm in the seminiferous tubules: Whether it is the maturation block at the sperm cell level, spermatocyte level, or spermatogonia level, it is called spermatogenesis block, and no complete spermatogenesis process is seen in any seminiferous tubule. However, since spermatogenesis is a dynamic process and spermatogenesis disorder in seminiferous tubules in different regions is significantly heterogeneous, the current testicular pathological classification standards cannot fully reflect the intrinsic spermatogenesis state, and a unified and standardized clinical diagnosis and treatment strategy and system are urgently needed.

[0003] Relying on the National Key R&D Program - Research on the Etiology and Clinical Prevention and Treatment of Spermatogenesis Disorders (2022YFC2702700), Li Zheng's team from Shanghai Jiao Tong University, based on a clinical sample library of 9,615 patients with spermatogenesis disorders and a family sample library of 504 cases, comprehensively considered the patients' spermatogenesis, and innovatively proposed to divide spermatogenesis disorders into three subtypes from five dimensions: clinical phenotype, cause of disease, course of disease, treatment and prognosis: 1) The seminiferous tubules have different morphologies, most tubules are without sperm, and only isolated tubules have sperm. "Focal type"; 2) The seminiferous tubules are similar in morphology, and the differentiation of spermatogenic cells is blocked in spermatocytes and spermatids. "Blocked type"; 3) The seminiferous tubules are destroyed or atrophied, with only supporting cells or occasional spermatogonia. "Exhaustion type". Among them, about 60% of "blocked type" spermatogenesis disorders are caused by genetic factors. Therefore, it is urgent to develop a new tool for efficient and accurate genetic diagnosis of such patients.

[0004] With the completion of the human genome sequencing project and the development of high-throughput sequencing technology, researchers in the medical field have a deeper understanding of the human genome, and the research on disease genetic variation, the function and mechanism of pathogenic genes has gradually deepened. The more mature whole exome sequencing (WES) technology currently uses an exon capture kit to capture the gene sequence of the exons of the entire gene and its surrounding areas, and then performs high-throughput sequencing. It has emerged in various genetic disease studies due to its low cost and high output data rate. In recent years, the cost of sequencing has dropped significantly from nearly 10,000 yuan to 100 yuan, making it possible to use it as a routine clinical test.

[0005] However, the current detection of spermatogenesis disorders still has the following defects: (1) The detection content is single, covering fewer gene loci, and has limited functions for scientific research exploration and discovery of new targets; (2) The classification is unclear, and only a few gene loci are tested for idiopathic azoospermia, which has limited guidance for clinical diagnosis and treatment; (3) The gene collection method is simple. At present, most panel designs are only based on guidelines and limited literature collection, and there is little comprehensive analysis based on large-scale sequencing platform results, public databases and text mining technology; (4) The information analysis method process is cumbersome. The bioinformatics analysis of offline data requires step-by-step evaluation and step-by-step completion of the results. The steps are cumbersome, time-consuming, and low in portability, which cannot meet the current analysis needs. Summary of the invention

[0006] The purpose of the present invention is to overcome the defect of the lack of effective spermatogenesis disorder detection technology in the prior art, and to provide a method for designing a gene panel detection for "blocking type" spermatogenesis disorder. The panel contains all types of genes used for the detection of "blocking type" spermatogenesis disorder, has a wide gene coverage, can be used in various stages from risk assessment of such diseases to diagnosis, treatment, prognosis, etc., and has strong portability, and is suitable for sequencing instruments currently on the domestic market or newly developed detection platforms.

[0007] In order to achieve the above object, the present invention provides a method for preparing a gene detection panel for "blocked" spermatogenesis disorder, comprising the following steps:

[0008] Step 1: Screen the information of "blocked" spermatogenesis disorder and its related genes, and establish a local database; Step 2: Select "blocked" spermatogenesis disorder related genes from the publicly available literature resources, including: "blocked" spermatogenesis disorder genetic pathogenic genes in the public database, genes with "blocked" spermatogenesis disorder phenotype in mice after knockout / mutation and homologous genes in humans, and genes related to "blocked" spermatogenesis disorder reported in the publicly available literature;

[0009] Step 3: Merge the "blocked" spermatogenesis-related genes in step 2, remove redundancy, and determine the standard gene name through the NCBIoffice name or HGNC approved Official Symbol system to obtain the "blocked" spermatogenesis detection chip gene set;

[0010] Step 4: Select the target gene region for probe design: For the genes collected in steps 1 and 2, if the specific mutation location is clear, select the target region based on the clear gene locus coverage area; for gene regions with relatively concentrated or dense locations, select exons as target regions; for important genes that are highly related to "blocked" spermatogenesis disorders, select regions of all variable splicing types as target regions;

[0011] Step 5: Extend both ends of the gene target region selected in step 4, with a default length of 50 bp, merge all selected regions and remove redundancy, and finally form a bed file for probe design, which contains the chromosome number of the target region, the starting position of the target region, the ending position of the target region, and custom information;

[0012] Step 6, panel probe design: according to the target region selected in step 4, find the design region where probes can be designed from the designable probe data set in the human genome, and generate probes according to the design region and probe design parameters;

[0013] Step 7, probe design evaluation: compare the important sites and all target areas that are highly related to "blocked" spermatogenesis disorders that have been screened with the probe design area selected in step 6, and calculate the coverage of the important sites and the coverage of all target areas covered by the probes. The calculation formula is: coverage = mapping reads / target sequencing reads. If the coverage requirements of total coverage ≥ 90% and important site coverage ≥ 99% are met, the next step of panel synthesis can be entered; if not, it is necessary to select a suitable probe near the target area;

[0014] Step 8, panel synthesis: Add fixed amplification sequences to both ends of the probe designed in step 7, synthesize single-stranded DNA, amplify by PCR, transcribe into RNA probe, add biotin label, and obtain the "blocking type" spermatogenesis disorder gene detection panel.

[0015] Preferably, step one specifically includes collecting testicular tissue, peripheral blood samples and clinical information from patients with "blocked" spermatogenesis disorders, clarifying the pathological phenotype based on histological staining, and excluding the presence of known spermatogenesis-related causes; taking 3 ml of peripheral blood for whole exome sequencing, using High Sensitivity DNA Assay and Qubit2.0 to evaluate the size, quantity and quality of the sequencing library, using the Illumina NovaSeq platform for 2×150bp paired-end high-throughput sequencing of qualified libraries, using the human reference genome (hg19 / GRCh37) for alignment, annotating multiple databases through ANNOVAR3, and classifying the pathogenicity of variants according to the American College of Medical Genetics and Genomics. After obtaining the sequencing results, pathogenic genes are screened based on the variant frequency being less than 1% in gnomAD, the variant type being a loss-of-function variant, testis-specific high expression, and reports related to spermatogenesis disorders in the literature, and the candidate pathogenic genes are verified by Sanger sequencing of the peripheral blood genome of patients and families.

[0016] Preferably, the collection of genetic pathogenic genes of "arrest-type" spermatogenesis disorders in the public database described in step 2 is performed by filtering the search data of the "azoospermia" and "maturation arrest" terms in OMIM, and only including genes related to spermatogenic cell maturation arrest, including spermatogonia arrest, spermatocyte arrest and spermatid arrest.

[0017] Preferably, the collection of the knockout / mutated mouse phenotype of "arrest of spermatogenesis" and homologous genes in humans in step 2 is through the collection of the genes in the MGI (Mouse Genome Informatics) database in which the knockout / mutated mouse has a reproductive system phenotype and the word "arrest of spermatogenesis" is included in the phenotype description, and the human homologous genes are searched through the homologene database of NCBI.

[0018] Preferably, the collection of genes reported in the published literature described in step 2 is to screen out important genes in the literature through existing technology text mining, and the key parameters of text mining include "spermatogenesis", "meiosis", "sperm deformation", "male infertility", "azoospermia", "non-obstructive azoospermia", "spermatogenesis disorder", "spermatogenesis block", "meiotic block", "spermatogonia block", "spermatocyte block", "spermatocyte block", and "genetic variation". A vocabulary is established through keywords, and the "and / or" connection between the keywords is selected. The NCBIPubmed literature is mined through a script, and finally the important genes related to "blocked" spermatogenesis disorder are screened out from the selected literature of text mining.

[0019] Preferably, the probe designable data set in step 6 is a data set for capture probe design formed after removing the Alu repeat regions, tandem repeat regions, and regions with high repetitiveness or low assembly quality in pseudogenes of the genome.

[0020] Preferably, when designing the panel probe in step 6, the probe design coverage of the design area is weighted. The coverage weighted data is based on the whole genome sequencing data to predict that some areas have too high or too low depths, and these areas are quantitatively marked to achieve the purpose of the final designed probe to evenly capture the target area, wherein the weighting formula is as follows:

[0021]

[0022] In the formula, x1, x2, x3…xk are data that are higher or lower than the average probe depth, f1, f2, f3…fk are weights corresponding to the respective probe depth data, and k is the number of depth statistics that are too high or too low, which refers to the average probe depth.

[0023] Preferably, the "blocking type" spermatogenesis disorder gene detection panel is fixed on a silicon wafer or a glass slide of a gene chip; or a liquid phase reaction pool is used, and the RNA single-stranded probe is not fixed on a solid phase carrier.

[0024] The present invention also provides a gene detection panel for "blocked" spermatogenesis disorder, wherein the panel is used to detect a gene set including the following genes: TDRKH, EHMT2, SLC4A2, MEIKIN, SPATA22, TOPAZ1, BSG, BTRC, ENTPD5, DICER1, GNPAT, SPATA16, EWSR1, CLPP, ZSCAN21, AKAP9, TBPL1, NSMF, GTSF1, DHH, LHB, RNF212, BRIP1, MAP2, MAP7, MOV10L1, PATZ1, SLC19A2, BTBD18, MEIG1, CDC7, UPF3A, SOX30, SETX, EHD1, STAG3, AGO4, DMRTC2, SPDYA, ATM, MEI1, MEI4, BRCA1, BRCA2, M1AP, SCML2, BOLL, ING2, GNRHR, TOP3B, NDC1, CNTD1, TEX11, TEX12, TEX 14. NME5, TEX15, SIRT1, DUSP6, RAD51C, DMC1, CKS2, CEP63, PSMC3IP, PPP2CA, HSF2, LMNA, ASZ1, KISS1R, MGAT2, PAIP2, STX2, RANBP1, BIK, USP9Y, RANBP 9. MLH1, MLH3, MAD2L2, TRIP13, BRDT, PRDM9, ARID4B, CIB1, PRDM1, HOXA11, HOXA10, PPP1CC, PAIP2B, SCMH1, MEIOC, MAEL, MEIOB, NANOS1, CCDC155, HFM1 , LMTK2, CCNB1IP1, TERB1, MSH4, MSH5, FKBP6, DDX4, YTHDC1, YTHDC2, CREM, KLHL10, UBR2, PLD6, FBXO43, AK7, HSPBP1, NKAPL, SYCE3, STRA8, SYCE2, SYCE 1. SOHLH1, UBB, SOHLH2, MORC1, MORC2, KL, HSPA4, TDRD9, HMGA2, HSPA2, TDRD6, TDRD5, ZC3HC1, TDRD1, KIF18A, CDK2, CDK1, TDRD12, PIN1, EIF4G3, ZMYND 15. PIWIL2, PIWIL1, RHOXF2, PIWIL4, GAL3ST1, MCMDC2, MCM8, SYCP1, SPO11, MCM9, YBX2, AFF4, INSL6, DNMT3L, SIX5, DMRTB1, RNF17, HORMAD2, HORMAD1,MYBL1, RBM5, SUN1, HSP90AA1, H2AFX, DNMT3A, NRG1, SAFB, TSN, IQCG, SMC1B, CCNA1, MCPH1, GTF2A1, SHCBP1L, KATNB1, NR2 C2, CLCN2, NXF2, POC1A, SLC12A2, MND1, REC8, BAX, SYCP3, SLC25A31, SYCP2, RAD21L1, SIAH1, TEX19, SPOCD1, SGO2, SHOC1. ,

[0025] The present invention also provides an application of a "blocking type" spermatogenesis disorder gene detection panel, wherein the "blocking type" spermatogenesis disorder gene detection panel is used to prepare any one of a gene chip, a "blocking type" spermatogenesis disorder detection device, and a "blocking type" spermatogenesis disorder detection kit.

[0026] Compared with the prior art, the beneficial effects of the present invention include at least:

[0027] (1) The data involved in the present invention come from a wide range of sources. By mining the sequencing data in currently recognized commonly used databases and published literature, the genes finally selected have a wide coverage and are highly correlated with "blocked" spermatogenesis disorders, which in turn helps to improve the performance and accuracy of the detection.

[0028] (2) The present invention includes the detection results of high-throughput sequencing. This part is aimed at the gene variation detection results of patients with "blocking type" spermatogenesis disorders to screen out the pathogenic genes, so the designed gene panel is more suitable for the detection of "blocking type" spermatogenesis disorders.

[0029] (3) The gene panel developed by the present invention is suitable for independently developed sequencing instruments. Compared with the detection methods currently used by commercial companies, the panel detection platform of the present invention has lower costs for gene detection and analysis, a wider range of applications, and great promotion value. DETAILED DESCRIPTION

[0030] The technical solution of the present invention is further described below in conjunction with embodiments.

[0031] The gene set in this article is a collection or combination of all genes related to "blocked" spermatogenesis disorders.

[0032] Gene detection panel is a term used after the development of high-throughput gene detection and gene sequencing. It refers to designing probes corresponding to several genes on the same capture chip to capture target DNA for subsequent gene sequencing. In the detection, not only one site or one gene is detected, but multiple sites, multiple genes, and multiple sites are detected at the same time. These sites and genes need to be selected and combined according to a standard, which requires a detection panel.

[0033] In the following experiments, library construction and hybridization capture both include an amplification step, in which the primers / tags all use universal sequences, the universal adapter primer sequences are shown in SEQ ID NO: 1 to SEQ ID NO: 8, the short adapter sequences are shown in SEQ ID NO: 1 to SEQ ID NO: 2, the tag adapter sequences are shown in SEQ ID NO: 3 to SEQ ID NO: 6, the amplification primer sequences are shown in SEQ ID NO: 7 to SEQ ID NO: 8, the hybridization process uses the probe of the target gene, the primer of the target gene STAG3 is provided, the STAG3 probe sequence is shown in SEQ ID NO: 9 to SEQ ID NO: 18, and the i5 and i7 index sequences are shown in Table 1 below.

[0034] Table 1 i5 and i7 index sequence information

[0035]

[0036]

[0037]

[0038]

[0039]

[0040] 1. DNA Extraction from Peripheral Blood

[0041] 1) In accordance with relevant national policies and regulations and with the consent of the subjects, 2-5 ml of peripheral venous blood was drawn from the proband, placed in an EDTA anticoagulant tube, and frozen at -80°C for later use;

[0042] 2) Take 200 μl of frozen blood, add 20 μl of Proteinase K solution, and mix well;

[0043] 3) Add 200 μl of buffer GB, mix thoroughly by inversion, and place at 70°C for 10 min. The solution should become clear and centrifuge briefly to remove water droplets on the inner wall of the tube cap.

[0044] 4) Add 200 μl of anhydrous ethanol and vortex thoroughly for 15 seconds. Flocculent precipitation may appear at this time. Centrifuge briefly to remove water droplets on the inner wall of the tube cap.

[0045] 5) Add the solution and flocculent precipitate obtained in the previous step to an adsorption column CB3 (the adsorption column is placed in a collection tube), centrifuge at 12,000 rpm (13,400 g) for 30 seconds, discard the waste liquid, and put the adsorption column CB3 back into the collection tube;

[0046] 6) Add 500 μl of buffer GD to the adsorption column CB3 (please check whether anhydrous ethanol has been added before use), centrifuge at 12,000 rpm (13,400 g) for 30 seconds, discard the waste liquid, and place the adsorption column CB3 in a collection tube;

[0047] 7) Add 600 μl of rinse solution PW to the adsorption column CB3 (please check whether anhydrous ethanol has been added before use), centrifuge at 12,000 rpm (13,400 g) for 30 seconds, discard the waste liquid, and place the adsorption column CB3 in a collection tube;

[0048] 8) Repeat the operation of adding 600 μl of rinsing solution PW once;

[0049] 9) Place the adsorption column CB3 back into the collection tube, centrifuge at 12,000 rpm (13,400 g) for 2 min, and discard the waste liquid. Place the adsorption column CB3 at room temperature for several minutes to completely dry the residual rinse liquid in the adsorption material;

[0050] 10) Transfer the adsorption column CB3 into a clean centrifuge tube, add 40 μl of deionized water to the middle part of the adsorption membrane, let it stand at room temperature for 2-5 minutes, centrifuge at 12,000 rpm (13,400 g) for 2 minutes, and collect the solution into the centrifuge tube.

[0051] 2. DNA fragmentation

[0052] 1) Add a total of 200 ng of DNA to a PCR tube in a volume of 40 μl (VDNA+Vwater);

[0053] 2) Prepare the enzyme digestion mix on an ice box according to Table 2 below:

[0054] Table 2 Preparation of enzyme digestion mix

[0055] Reagent components 1 reaction (μl) Fragmentation Buffer (Fragment&ERABuffer) (yellow) 10 Fragment & ERA Enzyme Mix (yellow) 10 Total volume 20

[0056] 3) Take 20 μl of Mix into the PCR tube containing the template, mix well, and centrifuge briefly;

[0057] 4) On the PCR instrument, heat the cover to 85°C, 4°C for 1 min (pause to place samples), 37°C for 6 min, 65°C for 30 min, and hold at 4°C.

[0058] 3. Connect the connector

[0059] 1) Prepare the connection Mix on the ice box according to Table 3 below:

[0060] Table 3 Connection Mix configuration

[0061] Reagent components 1 reaction (μl) Ada Ligation Buffer (blue) 30 DNA ligase (Ada Ligase) (blue) 10 Nuclease-Free Water 5 Total volume 45

[0062] 2) Add 5 μl of PE short connector (Adapter) to the restriction digestion tube in the previous step;

[0063] 3) Add 45 μl of ligation mix, mix gently, and centrifuge;

[0064] 4) Place in PCR instrument at 22°C for 15 min, hold at 4°C.

[0065] 4. Purification of Ligation Product

[0066] 1) Add 88 μl of purified magnetic beads to the PCR amplification product; mix well, incubate at room temperature for 5 min, centrifuge, magnetically absorb, and discard the solution;

[0067] 2) Prepare 80% ethanol;

[0068] 3) Keep the PCR tube on the magnetic rack, carefully remove the supernatant, add 200 μl 80% ethanol to the PCR tube, and discard the supernatant within 30 seconds;

[0069] 4) Repeat step 3) once, a total of 22 times, discard the liquid, and dry;

[0070] 5) Add 22 μl Nuclease-Free Water, mix well, incubate at room temperature for 2 min, centrifuge briefly, magnetically aspirate, and aspirate the supernatant into a new PCR tube.

[0071] 5. PCR amplification and purification

[0072] 1) Add 25 μl 2× High-Fidelity Library Amplification MIX (PCR Master Mix) (white) to the ligation product;

[0073] 2) Add 5 μl of UDI primer (Index primer) (white) to each tube (record the Index number clearly), mix well, and centrifuge.

[0074] 3) Set the PCR instrument program according to Table 4 below and perform amplification:

[0075] Table 4 PCR instrument program

[0076]

[0077] 4) Add 50 μl of magnetic beads to the PCR amplification product; mix well, incubate at room temperature for 5 min, centrifuge, magnetically absorb, and discard the solution;

[0078] 5) Prepare 80% ethanol;

[0079] 6) Keep the PCR tube on the magnetic rack, carefully discard the supernatant, add 200 μl 80% ethanol to the PCR tube, and discard the supernatant within 30 seconds;

[0080] 7) Repeat step 6) once, twice in total, discard the liquid, and dry;

[0081] 8) Add 100μ1 Nuclease-Free Water, mix well, incubate at room temperature for 2 minutes, centrifuge, magnetically aspirate, and aspirate the supernatant into a new EP tube. (Note: At this point, the pre-library can be directly captured in the next step or stored at -20℃.

[0082] 6. Pre-library quantification

[0083] The concentration of the pre-library is generally greater than 20 ng / μl.

[0084] 7. Hybridization Capture

[0085] 1) Take 750 ng of one library and add it to a PCR tube and mark it; if there are multiple libraries (up to 8 libraries), take 375 ng of the library and add it to an EP tube;

[0086] 2) Add 1.8 times the volume of purified magnetic beads, mix well, incubate at room temperature for 5 min, centrifuge, magnetically absorb, and discard the solution;

[0087] 3) Prepare 80% ethanol;

[0088] 4) Keep the PCR tube on the magnetic rack, carefully discard the supernatant, add 200 μl 80% ethanol to the PCR tube, and discard the supernatant within 30 seconds;

[0089] 5) Repeat step 4) once, twice in total, discard the liquid and dry;

[0090] 6) Prepare hybridization mix on an ice box according to Table 5 below:

[0091] Table 5 Preparation of hybrid mix

[0092]

[0093] 7) Add 28 μl of hybridization mix to the dried PCR tube, vortex for 30 seconds to ensure that the DNA dried at the bottom of the tube is dissolved, centrifuge, magnetically aspirate, and take the supernatant to a new PCR tube;

[0094] 8) Add 2 μl of hybridization capture probe, mix well, spin off instantly, and [thaw on ice];

[0095] 9) Place on PCR instrument, heat cover at 85℃, 80℃ for 5 min, hold at 50℃ (incubation time is 12-18h, usually 16h).

[0096] 8. Prepare Capture Magnetic Beads

[0097] 1) Remove the capture beads from 4°C, vortex and resuspend, and equilibrate at room temperature for 30 minutes;

[0098] 2) Take 50 μl of capture magnetic beads and add them to a new PCR tube. Place it on a magnetic rack for 1 min to allow the solution to clarify and remove the supernatant.

[0099] 3) Remove the PCR tube from the magnetic stand, add 180 μl of magnetic bead binding buffer, gently pipette several times to mix, and resuspend the magnetic beads;

[0100] 4) Place on the magnetic stand for 1 min and remove the supernatant;

[0101] 5) Repeat step 4) 2 times, washing the magnetic beads 3 times in total;

[0102] 6) Remove the PCR tube from the magnetic stand, add 180 μl of magnetic bead binding buffer, and gently pipette to resuspend and mix the magnetic beads for later use.

[0103] 9. Capture target region DNA library

[0104] 1) Take out Wash Buffer 2 and preheat it to 50℃ in advance;

[0105] 2) Keep the hybridization product on the PCR instrument, add 180 μl of the resuspended capture magnetic beads to the hybridization product, pipette to mix, and transfer to a new 1.5 ml EP tube, cover the tube, and place it on a rotary mixer at room temperature for 30 minutes. During this period, take it off the vortex for 10 seconds every 10 minutes to prevent the magnetic beads of some samples from not mixing evenly;

[0106] 3) After 30 minutes, remove the EP tube, centrifuge it briefly, place the EP tube on a magnetic rack for 2 minutes to clarify the solution, and remove the supernatant;

[0107] 4) Add 150 μl Wash Buffer 1 to the EP tube, gently pipette to mix, place on a rotary mixer to wash for 15 min, then centrifuge, place the EP tube on a magnetic rack for 2 min to clarify the solution, and remove the supernatant.

[0108] 5) Place the 1.5ml EP tube containing magnetic beads on a metal bath, add 150μl 50℃ preheated Wash Buffer 2, gently pipette to mix, cover the tube, and incubate at 50℃ on a metal bath for 10min. (If there are many samples, add all Wash Buffer 2 and then pipette or shake to mix;

[0109] 6) Centrifuge briefly, place the EP tube on a magnetic rack for 2 minutes to clarify the solution, and remove the supernatant;

[0110] 7) Repeat steps 5)-6) 2 times, washing the magnetic beads 3 times in total (Panel can be washed 4 times) (Note: replace the new EP tube for the last wash);

[0111] 8) Keep the sample on the magnetic rack, add 500 μl of 80% ethanol to the EP tube, discard within 30 seconds (a 10 μl pipette can be used to remove the residue), and let it dry;

[0112] 9) Add 24 μl Nuclease-Free Water to the EP tube and transfer the resuspended magnetic beads to a new PCR tube for later use.

[0113] 10. Capture Amplification

[0114] 1) Prepare capture PCR amplification Mix on an ice box according to Table 6 below:

[0115] Table 6 Capture PCR Amplification Mix

[0116] Reagent components 1 reaction (μl) Post PCR Maxter Mix (orange) 25 Post PCR Primer (Orange) 1 Total volume 26

[0117] 2) Add 26 μl of PCR Mix to the resuspended magnetic beads PCR tube and pipette to mix 6 times;

[0118] 3) Set the amplification program on the PCR instrument according to Table 7 below:

[0119] Table 7 Amplification procedures

[0120]

[0121] 11. Capture and Purification of Amplification Products

[0122] 1) Add 1.1 times the volume of purified magnetic beads (55 μl) to the PCR amplification product: mix well, incubate at room temperature for 3 min, centrifuge, magnetically absorb, and discard the solution;

[0123] 2) Prepare 80% ethanol;

[0124] 3) Add 200 μl of 80% ethanol to the sample tube, mix well, centrifuge, magnetically absorb, and discard the liquid;

[0125] 4) Repeat step 3) once, twice in total, discard the liquid and dry;

[0126] 5) Add 25 μl Nuclease-Free Water and mix well, incubate at room temperature for 2 minutes, centrifuge, magnetically aspirate, and aspirate the supernatant into the library tube. (Note: At this point, the captured library can be directly sequenced or stored at -20°C.)

[0127] 12. Capture Library Quantification

[0128] The concentration of the capture library is generally greater than 2 ng / μl (positively correlated with the number of hybridization samples).

[0129] 13. Melting of sequencing reagents

[0130] Thaw the sequencing reagents in advance, put the kit in a water tank, and place it in a water bath at room temperature for 2 hours until it is completely thawed (the water level does not exceed the water level line). Take out the Flow Cell from 4°C 30 minutes in advance and place it at room temperature.

[0131] 14. Capture Library Denaturation and Dilution

[0132] 1) Dilute the library to 4 nM, mix well, and centrifuge;

[0133] 2) Mix the library, take 5 μl of each sample into a new tube, mix well, and centrifuge;

[0134] 3) Qubit quantitative mixed library to obtain concentration (ng / μl);

[0135] 4) Prepare 0.2M NaOH, the pH value should be greater than 13, if it is less than 13, re-prepare;

[0136] 5) Denature and dilute according to Table 8 below:

[0137] Table 8 Capture library denaturation and dilution library

[0138]

[0139] 6) Prepare the sample for the machine. Dilute the library according to Table 9 below, mix well before loading, and centrifuge:

[0140] Table 9 Dilution of the library on the machine

[0141]

[0142] 15. Loading Sequencing Reagent Kit

[0143] 1) Place the 2 ml centrifuge tube containing the library into the corresponding library position of the kit. Cut off the centrifuge tube cap before placing the reagent into the instrument and make sure it is inserted to the bottom.

[0144] 2) Place the reagents in the corresponding unit position of the sequencer reagent refrigerator (A on the left, B on the right);

[0145] 3) Empty the waste container.

[0146] 16. Loading the sequencing chip

[0147] 1) Clean the dust on the surface and back of the chip: Wet the lens cleaning paper with anhydrous ethanol, wipe the glass surface of the chip, and wait for it to dry naturally (Note: wipe in one direction and avoid the inlet and outlet of the liquid);

[0148] 2) Use a dust-free cloth dipped in anhydrous ethanol to wipe the chip heating module and the chip loading area. When wiping, avoid the inlet and outlet of the manifold;

[0149] 17. Start sequencing

[0150] Check the computer's D and E disk memory. For dual-unit SE75+8 sequencing, D disk > 150G, E disk > 15T. When the memory is insufficient, the system will prompt and sequencing cannot start.

[0151] 1) Select the sequencing unit (A / B);

[0152] 2) Import the experimental information table (confirm sample name, idex);

[0153] 3) Loading sequencing chips and sequencing reagents;

[0154] 4) Confirmation of sequencing experiment information parameters;

[0155] 5) Sequencing run;

[0156] 6) Fluid path cleaning after sequencing.

[0157] 18. Data Analysis

[0158] The human reference genome (hg19 / GRCh37) was used for alignment. Multiple databases were annotated using ANNOVAR3, and the pathogenicity of variants was classified according to the American College of Medical Genetics and Genomics (ACMG).

[0159] 19. Handling of failed quality control samples

[0160] 1) The library concentration is not up to standard and subsequent sequencing cannot be performed. The reasons need to be investigated, including but not limited to samples, reagents, instruments, and personnel operations. A correction report should be written and the experiment should be repeated.

[0161] 2) If the NTC concentration added during pre-library construction exceeds 2 ng / μl, subsequent capture work can be performed if the sample volume allows, but generally no library will be captured.

[0162] A gene detection panel for "blocked" spermatogenesis disorder designed according to the present invention can be used to detect a gene set including the 190 genes in Table 10.

[0163] Table 10 Gene set for detection of “blocked type” spermatogenesis disorder

[0164]

[0165]

[0166] The gene detection panel prepared by the present invention can be used to prepare gene chips, "blocking type" spermatogenesis disorder detection devices, and "blocking type" spermatogenesis disorder detection kits.

[0167] In summary, the preparation method of the "blocked" spermatogenesis disorder gene detection panel of the present invention comprises: screening "blocked" spermatogenesis disorder information and related genes to obtain a gene set; selecting a gene target region; designing a panel probe; synthesizing an RNA single-stranded probe to obtain a gene detection panel. Using the gene detection panel designed by the present invention, only a small amount of peripheral blood is needed to efficiently perform genetic detection and accurate typing of spermatogenesis disorder, and the results have important guiding significance for the clinical diagnosis and treatment of such patients.

[0168] Although the content of the present invention has been described in detail through the above preferred embodiments, it should be appreciated that the above description should not be considered as a limitation of the present invention. After reading the above content, it will be apparent to those skilled in the art that various modifications and substitutions of the present invention will occur. Therefore, the protection scope of the present invention should be limited by the appended claims.

Claims

1. A method for preparing a "blocking type" spermatogenesis disorder gene detection panel, It is characterized in that The following steps are involved: Step 1: Screen the information of "blocked" spermatogenesis disorders and their related genes and establish a local database: Step 2: Select genes related to "blocked" spermatogenesis disorders from publicly available literature resources, including: Genetic pathogenic genes of "blocked" spermatogenesis in public databases, genes that have a "blocked" spermatogenesis phenotype in mice after knockout / mutation and have homologous genes in humans, and genes related to "blocked" spermatogenesis reported in published literature; Step 3: Merge the "blocked" spermatogenesis-related genes in step 2, remove redundancy, and determine the standard gene name through the NCBI officename or HGNC approved Official Symbol system to obtain the "blocked" spermatogenesis detection chip gene set; Step 4: Select the target gene region for probe design: For the genes collected in steps 1 and 2, if the specific mutation location is clear, select the target region based on the clear gene locus coverage area; for gene regions with relatively concentrated or dense locations, select exons as target regions; for important genes that are highly related to "blocked" spermatogenesis disorders, select regions of all variable splicing types as target regions; Step 5: Extend both ends of the gene target region selected in step 4, with a default length of 50 bp, merge all selected regions and remove redundancy, and finally form a bed file for probe design, which contains the chromosome number of the target region, the starting position of the target region, the ending position of the target region, and custom information; Step 6, panel probe design: according to the target region selected in step 4, find the design region where probes can be designed from the designable probe data set in the human genome, and generate probes according to the design region and probe design parameters; Step 7, probe design evaluation: compare the important sites and all target areas that are highly related to "blocked" spermatogenesis disorders that have been screened with the probe design area selected in step 6, and calculate the coverage of the important sites and the coverage of all target areas covered by the probes. The calculation formula is: coverage = mapping reads / target sequencing reads. If the coverage requirements of total coverage ≥ 90% and important site coverage ≥ 99% are met, the next step of panel synthesis can be entered; if not, it is necessary to select appropriate probes near the target area; Step 8, panel synthesis: Add fixed amplification sequences to both ends of the probe designed in step 7, synthesize single-stranded DNA, amplify by PCR, transcribe into RNA probe, add biotin label, and obtain the "blocking type" spermatogenesis disorder gene detection panel.

2. The preparation method as claimed in claim 1, wherein step 1 specifically comprises collecting testicular tissue, peripheral blood samples and clinical information from patients with "blocked" spermatogenesis disorder, clarifying the pathological phenotype according to histological staining, and excluding the presence of known spermatogenesis-related causes; taking 3 ml of peripheral blood for whole exome sequencing, using High Sensitivity DNA Assay and Qubit2.0 to evaluate the size, quantity and quality of the sequencing library, using the Illumina NovaSeq platform for 2×150bp double-end high-throughput sequencing of the qualified library, using the human reference genome (hg19 / GRCh37) for comparison, annotating multiple databases through ANNOVAR3, and classifying the pathogenicity of the variant according to the American College of Medical Genetics and Genomics. After obtaining the sequencing results, the pathogenic gene screening is performed according to the variant frequency in gnomAD being less than 1%, the variant type being a loss-of-function variant, testis-specific high expression, and reports related to spermatogenesis disorder in the literature, and the candidate pathogenic gene is verified by Sanger sequencing of the peripheral blood genome of patients and families.

3. The preparation method according to claim 1, It is characterized in that The collection of genetic pathogenic genes of "arrest-type" spermatogenesis disorders in the public database described in step 2 was performed by filtering the search data of the terms "azoospermia" and "maturation arrest" in OMIM, and only genes related to spermatogenic cell maturation arrest were included, including spermatogonia arrest, spermatocyte arrest and spermatid arrest.

4. The preparation method according to claim 1, It is characterized in that The knockout / mutation mice with "arrest of spermatogenesis" spermatogenesis disorder phenotype described in step 2 are collected by searching the MGI (Mouse Genome Informatics) database for genes with reproductive system phenotypes in knockout / mutation mice and the word "arrest of spermatogenesis" in the phenotype description, and searching for their human homologous genes in the homologene database of NCBI.

5. The preparation method according to claim 1, It is characterized in that The collection of genes reported in the published literature described in step 2 is to screen out important genes in the literature through existing technology text mining. The key parameters of text mining include "spermatogenesis", "meiosis", "sperm deformation", "male infertility", "azoospermia", "non-obstructive azoospermia", "spermatogenesis disorder", "spermatogenesis block", "meiotic block", "spermatogonia block", "spermatocyte block", "spermatid block", and "genetic variation". A vocabulary is established through keywords, and the "and / or" connection between keywords is selected. The NCBIPubmed literature is mined through a script, and finally important genes related to "blocked" spermatogenesis disorder are screened out from the selected literature of text mining.

6. The preparation method according to claim 1, It is characterized in that The probe designable data set described in step 6 is a data set for capture probe design formed after removing the Alu repeat regions, tandem repeat regions, and pseudogene regions with high repetitiveness or low assembly quality in the genome.

7. The preparation method according to claim 1, It is characterized in that When designing panel probes in step 6, the probe design coverage of the design area is weighted. The coverage weighted data is based on the whole genome sequencing data to predict that some areas have too high or too low depths. These areas are quantitatively marked so that the final designed probe can evenly capture the target area. The weighting formula is as follows: In the formula, x 1 、x 2 、x 3 …x k is the data above / below the average probe depth, f 1 、f 2 、f 3 …f k is the weight corresponding to each probe depth data, k is the number of too high / too low depth statistics, and refers to the average probe depth.

8. The preparation method according to claim 1, It is characterized in that The "blocked" spermatogenesis disorder gene detection panel is fixed on a silicon chip or glass slide of a gene chip; or a liquid phase reaction pool is used, The RNA single-stranded probe is not fixed on a solid support.

9. A gene detection panel for "blocked" spermatogenesis disorder, It is characterized in that The panel is used to detect a gene set including the following genes: TDRKH, EHMT2, SLC4A2, MEIKIN, SPATA22, TOPAZ1, BSG, BTRC, ENTPD5, DICER1, GNPAT, SPATA16, EWSR1, CLPP, ZSCAN21, AKAP9, TBPL1, NSMF, GTSF1, DHH, LHB, RNF212, BRIP1, MAP2, MAP7, MOV10L1, PATZ1, SLC19A2, BTBD18, MEIG1, CDC7, UPF3A, SOX30, SETX, EHD1, STAG3, AGO4, DMRT C2, SPDYA, ATM, MEI1, MEI4, BRCA1, BRCA2, M1AP, SCML2, BOLL, ING2, GNRHR, TOP3B, NDC1, CNTD1, TEX11, TEX12, TEX14, NME5, TEX15, SIRT1, DUSP6, RAD51 C. DMC1, CKS2, CEP63, PSMC3IP, PPP2CA, HSF2, LMNA, ASZ1, KISS1R, MGAT2, PAIP2, STX2, RANBP1, BIK, USP9Y, RANBP9, MLH1, MLH3, MAD2L2, TRIP13, BRDT, PRDM9, ARID4B, CIB1, PRDM1, HOXA11, HOXA10, PPP1CC, PAIP2B, SCMH1, MEIOC, MAEL, MEIOB, NANOS1, CCDC155, HFM1, LMTK2, CCNB1IP1, TERB1, MSH4, MSH5 , FKBP6, DDX4, YTHDC1, YTHDC2, CREM, KLHL10, UBR2, PLD6, FBXO43, AK7, HSPBP1, NKAPL, SYCE3, STRA8, SYCE2, SYCE1, SOHLH1, UBB, SOHLH2, MORC1, MORC2 , KL, HSPA4, TDRD9, HMGA2, HSPA2, TDRD6, TDRD5, ZC3HC1, TDRD1, KIF18A, CDK2, CDK1, TDRD12, PIN1, EIF4G3, ZMYND15, PIWIL2, PIWIL1, RHOXF2, PIWIL4, GAL3ST1, MCMDC2, MCM8, SYCP1, SPO11, MCM9, YBX2, AFF4, INSL6, DNMT3L, SIX5, DMRTB1, RNF17, HORMAD2, HORMAD1, MYBL1, RBM5, SUN1, HSP90AA1, H2AFX,<h2 style=";text-align:left;direction:ltr">DNMT3A, NRG1, SAFB, TSN, IQCG, SMC1B, CCNA1, MCPH1, GTF2A1, SHCBP1L, KATNB1, NR2C2, CLCN2, NXF2, POC1A, SLC12A2, MND1, REC8, BAX, SYCP3, SLC25A31, SYCP2, RAD21L1, SIAH1, TEX19, SPOCD1, SGO2, SHOC1.

10. An application of a gene detection panel for "blocked" spermatogenesis disorder, It is characterized in that The "blocking type" spermatogenesis disorder gene detection panel is used to prepare any one of a gene chip, a "blocking type" spermatogenesis disorder detection device, and a "blocking type" spermatogenesis disorder detection kit.